Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type.

UroGen Pharma shares fell to a 52-week low after a Food and Drug Administration document indicated disagreements with the company about certain aspects of studies of bladder cancer drug UGN-102. The ...

UroGen Pharma (NASDAQ: URGN) shares plummeted 29% following concerns from FDA staff regarding the efficacy of its bladder ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic cancer.

UroGen’s shares drop 20% as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.

Financially, CG Oncology reported a net loss of $34.5 million for the three months ended March 31, 2025, compared to $16.9 ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

It was only a few words, but they turned Steve and Amanda Jones' world upside down.